December 11, 2013
Authored and Edited by Timothy P. McAnulty; Jeffrey A. Berkowitz
The USPTO recently published updated statistics for filings under the AIA’s new post-grant procedures. As of November 2013, just 14 months after the new post grant challenges went into effect, the USPTO has received over 700 total petitions. The vast majority of them are for inter partes review (IPR), over 600 petitions, although there continues to be a steady filing of petitions for covered business method patents. Of note, 22 covered business method (CBM) reviews were filed in fiscal year 2014 alone. This is already about half of the total number of CBM requests filed for all of fiscal year 2013.
Over 70% of post grant challenges concern electrical/computer patents. Requests in mechanical fields are a distant second at only about 15% of the total filings. Requests for chemical and bio/pharma patents represent about 8% and 6% of the total filings, respectively. Interestingly, there have been 6 IPR petitions filed against design patents.
After a challenger files its petition for either an IPR or CBM, the patent owner has the option of filing a preliminary response for the Board to consider before deciding if it will institute a proceeding. Patent owners are filing preliminary responses to only about half of the IPR and CBM requests. In 82 cases, the patent owner waived its right to file a Preliminary Response, effectively expediting the proceeding.
So far, the Board has issued 256 decisions on whether or not to institute a trial. It has instituted a total of 210 trials, has denied 36 petitions, and has joined 10 petitions to other trials. Considering IPR and CBM petitions together, the Board is instituting trials about 85% of the time. For instituted trials, there have been 57 disposals, including 52 settlements, 2 requests for adverse judgment, 1 dismissal, and 2 written final decisions by the Board.
Additional statistical information about filings under these AIA provisions is available at: http://www.uspto.gov/ip/boards/bpai/stats/aia_statistics_11_07_2013.pdf.
Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.